Abstract: A precursor of a C-terminal amidated peptide represented by the general formula P-X-Gly-Y.sub.n, wherein P is a peptide residue. X is an amino acid residue the C terminal of which (on the Gly side) can be converted in vivo to a --CONH.sub.2 group. Gly is a glycine residue, Y is a basic amino acid residue, n is an interger of 2 to 4 and a further amino acid residue other than Y or a peptide residue may be attached to Y.sub.n, is produced by a gene engineering technology. The precursor exhibits in vivo physiological activity like the C-terminal amidated peptide.
Abstract: Novel 5-pyrimidinecarboxamides useful for regressing or inhibiting the growth of leukemia and tumors. The compounds have the formula: ##STR1## wherein R.sub.1 is hydrogen or an alkoxy group having from one to four carbon atoms;R.sub.2 is hydrogen; alkyl, aryl, aralkyl, allyl, aralkenyl or aralkynyl, the alkyl, alkenyl or alkynyl moieties of which have from one to six carbon atoms, or a carbohydrate residue;R.sub.3 is hydrogen, C.sub.1 -C.sub.4 alkyl or aryl;R.sub.
Type:
Grant
Filed:
April 22, 1985
Date of Patent:
January 13, 1987
Assignees:
Uniroyal Chemical Company, Inc., Uniroyal Ltd.